DYNAMICURE
DYNAMICURE
Social Links:
Industry:
Biotechnology Health Care Medical
Founded:
2020-01-01
Address:
Waltham, Massachusetts, United States
Country:
United States
Website Url:
http://www.dynamicure.com
Total Employee:
11+
Status:
Active
Contact:
617-504-8407
Email Addresses:
[email protected]
Current Employees Featured
Official Site Inspections
http://www.dynamicure.com
- Host name: 68.183.248.16
- IP address: 68.183.248.16
- Location: Santa Clara United States
- Latitude: 37.3417
- Longitude: -121.9753
- Metro Code: 807
- Timezone: America/Los_Angeles
- Postal: 95051
More informations about "DynamiCure"
About Us - Dynamicure
Driven by science and passionate about advancing patient care, DynamiCure is translating potentially revolutionizing new insights on immuno-normalization into a pipeline of innovative …See details»
DynamiCure - Crunchbase Company Profile & Funding
DynamiCure is located in Waltham, Massachusetts, United States. Who are DynamiCure 's competitors? Alternatives and possible competitors to DynamiCure may include BionPharma , Cydan , and Trevarx Biomedical .See details»
DynamiCure Biotechnology - Org Chart, Teams, Culture & Jobs
DynamiCure Biotechnology 0 followers Driven by science and passionate about advancing patient care, DynamiCure is translating breakthrough insights on immuno-normalization into a pipeline …See details»
Dynamicure Biotechnology Company Profile | Management and
Dynamicure Biotechnology Profile and History. Dynamicure Biotechnology LLC is a company that operates in the Biotechnology industry. It employs 21-50 people and has $1M-$5M of revenue.See details»
DynamiCure Biotechnology - LinkedIn
DynamiCure Biotechnology | 3,234 followers on LinkedIn. Novel Targets. Pioneering Progress for Patients. | Driven by science and passionate about advancing patient care, DynamiCure is translating ...See details»
Dynamicure Biotechnology - Overview, News & Similar companies ...
Who is Dynamicure Biotechnology. Dynamicure Biotechnology LLC is a company that operates in the Biotechnology industry. It employs 21-50 people and has $1M-$5M of revenue. The comp …See details»
DynamiCure Biotechnology - VentureRadar
DynamiCure is pioneering the field of drug discovery by translating breakthrough immuno-normalization insights into a robust pipeline of innovative therapeutic antibody candidates. …See details»
DynamiCure - Updates, News, Events, Signals & Triggers
DynamiCure is focused on developing anti-CD93 constructs, including antibodies that target CD93, which may have therapeutic applications in cancer and autoimmune diseases. The …See details»
DynamiCure - Crunchbase
DynamiCure is advanced care to treat cancer, autoimmune, and other diseases.See details»
DynamiCure - Contacts, Employees, Board Members, Advisors
DynamiCure is advanced care to treat cancer, autoimmune, and other diseases.See details»
Dynamicure - Company Profile - Tracxn
Oct 30, 2024 Dynamicure ranks 544th among 788 active competitors. 282 of its competitors are funded while 189 have exited. Overall, Dynamicure and its competitors have raised over …See details»
Our Approach - Dynamicure
The Value of Partnering with DynamiCure. In our quest to find novel targets and better understand the mechanisms involved in immuno-normalization, we have implemented a collaborative …See details»
DynamiCure - Biotech Careers
DynamiCure is developing a pipeline of antibody candidates to treat cancer, autoimmune, and other diseases. Business Areas: Antibodies, Therapeutics, Cancer TherapeuticsSee details»
DCBY02 - Drug Targets, Indications, Patents - Synapse - Patsnap
About DynamiCure DynamiCure is employing a platform-agnostic approach to discover and develop therapeutics designed to address significant unmet medical needs in oncology and …See details»
What is Dynamicure Biotechnology? Company Culture, Mission, …
Dynamicure Biotechnology. Is this your company? This employer has not claimed their Employer Profile and is missing out on connecting with our community. Connect with our community. …See details»
DynamiCure - Work in biotech
DynamiCure’s lead program, DC-6001, interferes with the CD93 pathway and is hoped to switch the TME from an immunosuppressive to an immunostimulatory environment. CD93 is a novel …See details»
DynamiCure Announces Appointment of Industry Veteran Peter …
Waltham, MA — September 20, 2022 — DynamiCure, a private biopharmaceutical company translating pioneering immuno-normalization insights into a pipeline of innovative therapeutic …See details»
Phase I trial of lead antibody candidate launched
Nov 15, 2022 Oliver Rosen, President & Chief Medical Officer of DynamiCure, said: “By targeting CD93, DCBY02 represents a new and differentiated approach to vascular …See details»
Types of Corporate Culture and Examples for Leaders | ClickUp
1 day ago ClickUp is the dream company for those who want to work in a values-driven organization with lots of freedom and collaboration. The culture thrives on constant innovation, …See details»
News & Publications - Dynamicure
Nov 8, 2022 The lead candidate from DynamiCure’s anti-CD93 program, DCBY02 targets a wide range of metastatic solid tumors Phase 1 trial aims to assess the safety and anti-tumor activity …See details»